Sept 19 (Reuters) - Perrigo Co said it received final approval from U.S. health regulators for Ciclopirox topical solution, a generic version of Sanofi-Aventis' Penlac nail-fungus treatment. The ...
Co announces that it has received final approval from the FDA to manufacture and market Ciclopirox Topical Solution, 8%. Shipments will begin immediately. The product has been determined to be ...
Onychomycosis is the most common disease of nails, with a prevalence of up to 14% in Western adult populations. Whereas tinea unguium refers strictly to dermatophyte fungal infection of the nail plate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback